NeRRe Therapeutics is a clinical-stage company developing the neurokinin(NK)-1 receptor antagonist orvepitant for the treatment of common, chronic, and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction.Our focus with orvepitant is on the disabling chronic cough associated with the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF) for which t...
NeRRe Therapeutics is a clinical-stage company developing the neurokinin(NK)-1 receptor antagonist orvepitant for the treatment of common, chronic, and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction.Our focus with orvepitant is on the disabling chronic cough associated with the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF) for which there is no approved treatment.NeRRe will now evaluate orvepitant as a treatment for chronic cough in patients with IPF, a rare, progressive, and fatal form of interstitial lung disease
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.